• Thursday, Sep 29, 2022
  • Last Update : 10:24 am

DGDA approves Buet’s OxyJet for limited use

  • Published at 02:48 pm July 29th, 2021
OxyJet team conducts clinical trial phase I on a healthy volunteer under the supervision of medical doctors at BUET Courtesy

Its use can help prevent ICU admissions, claims the team behind OxyJet

Bangladesh has approved a limited production and use of OxyJet, an inexpensive alternative to the costly high-flow nasal cannula devices, invented by Bangladesh University of Engineering and Technology (Buet) to meet Covid-19 patients’ oxygen needs.

Directorate General of Drug Administration (DGDA) Deputy Director Md Salahuddin confirmed the matter on Wednesday.

Two hundred units of the device would be produced for use initially, he said.

Production on a large scale would be considered after observing how well the devices worked, whether there were any side effects in patients and if any improvements could be made, added Salahuddin.

OxyJet, a low-cost non-invasive ventilator invented by a group of teachers and students of Buet, has been designed with Covid-19 patients’ treatment in mind.

Phase II of OxyJet’s clinical trial is conducted on less severe hypoxemic patients under the supervision of doctors at DMCH Courtesy

Also Read - Linde Bangladesh to continue medical oxygen import from India

The device can provide 60 litres of oxygen per minute with up to 100% concentration without any electricity. Interim data of clinical trials have shown that its efficacy is non-inferior to traditional high-flow nasal cannula devices, according to the team behind the product.

Moreover, OxyJet uses 30% less oxygen when compared to HFNC devices for an equivalent clinical outcome, according to Buet’s mHealth Research group’s website.

Infographic shows how OxyJet functions Courtesy

According to its inventors, the device can provide high levels of oxygen to patients suffering from acute respiratory problems without having to shift them to the ICU.

Dr Toufiq Hasan, leader of the team and associate professor at Buet’s biomedical engineering department, said the use of OxyJet in hospitals would alleviate the pressure on intensive care wards as patients could be treated in general beds.

Continuous Positive Airway Pressure (CPAP) devices that are used to provide high pressure oxygen to critical patients cost around Tk1 lakh while HFNC devices sell for Tk4-5 lakh.

In contrast, the entire setup of OxyJet costs around Tk20,000-25,000, which will drop further if produced in bulk, claims the OxyJet team.

Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail